SCHEMBL3204154

SCHEMBL3204154

OC[C@@H](O)COc1ccc(N(Cc2cncs2)c2ccc(OC(F)F)c(OC(F)F)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.34
MAP4K4 O95819 1/20 0.34
PRKCD Q05655 1/20 0.34
MINK1 Q8N4C8 1/20 0.34
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
PARP15 Q460N3 1/20 0.32
PARP10 Q53GL7 1/20 0.32
HRH4 Q9H3N8 1/20 0.32
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
AR P10275 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250047 0.92 TSHR (0.39) TSHRMAPK1HRH4KMT2AMEN1
SCHEMBL3201882 0.92 TSHR (0.39) TSHRMAPK1HRH4KMT2AMEN1
SCHEMBL3203614 0.83 ALDH1A1 (0.42) TRPM8MAP4K4PRKCDMINK1TSHR
SCHEMBL3202266 0.83 TSHR (0.34) TSHRMAPK1HRH4PDE4B
SCHEMBL3201809 0.81 PDE4A (0.39) KMT2AMEN1PDE4BPDE4D
SCHEMBL3122844 0.79 PDE4A (0.40) PARP15PARP10PDE4BPDE4D
SCHEMBL3191879 0.79 PARP15 (0.46) TRPM8PARP15PARP10HRH4PDE4B
SCHEMBL3203145 0.79 PDE4D (0.37) TRPM8PARP15PARP10HRH4PDE4B
SCHEMBL3208426 0.79 ACLY (0.34) TRPM8HRH4PDE4BPDE4D
SCHEMBL3217097 0.78 HRH4 (0.34) HRH4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B TRPM8 3474/4885MAP4K4 497/4885PRKCD 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.